Kate Bingham joined SV Health Investors in 1991 and is one of the Managing Partners managing numerous venture capital funds, including the Impact Medicine Fund, Dementia Discovery Fund (DDF), and one public fund (International Biotechnology Trust) for life sciences investing.
Kate co-leads biotech investments and activities and her investments include small-molecule, biotherapeutic and gene therapy drug discovery and development projects as well as drug discovery platforms in a broad range of clinical areas. In her 30 years at SV, Kate’s biotech investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.
Prior to joining SVHI, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm. Kate has a first-class degree in Biochemistry from Oxford University and graduated from Harvard Business School with an MBA (Baker Scholar).
In May 2020, Kate was appointed Chair of the UK Vaccine Taskforce reporting to the Prime Minister to lead UK efforts to find and manufacture a COVID-19 vaccine on a six-month engagement stepping down as Chair in December 2020. On 8 December 2020 the UK started COVID-19 vaccinations – the first Western country to do so.